Device Trial Radar · NCT05679180
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
Last checked: Nov 19, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 11, 2023
Primary completion
May 24, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- University Hospital, BordeauxAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).
Conditions
- Central Serous Chorioretinopathy
Interventions
micropulse laserDevice
treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- central macular thicknessTime frame: Month 3
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.